Hodgkin Lymphoma: Tislelizumab with Gemcitabine and Cisplatin

We are studying a combination of tislelizumab, gemcitabine, and cisplatin for patients with relapsed or refractory Hodgkin lymphoma. The goal is to see if this treatment improves survival and response rates.

>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cisplatin
Cisplatin is a substance used in chemotherapy to kill or stop the growth of cancer cells.
Gemcitabine
Gemcitabine is a substance that slows or stops cancer cell growth and is used to treat several cancers, including pancreatic and lung.
Pegfilgrastim
Pegfilgrastim is a substance that boosts white blood cell production to lower infection risk after chemotherapy.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Cliniques Universitaires Saint-Luc
Hematology
Sint-Stevens-Woluwe, Belgium
Aarhus University Hospital
Hematology
Århus, Denmark
Rigshospitalet
Hematology
Copenhagen, Denmark
Sponsor: Haemato Oncology Foundation For Adults Netherlands (HOVON)
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.